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Poster Session-I 47weight, a T cell dose comparable to bone marrow transplant, in
a complete product with the exception of incidental losses that occur
during the process of T cell depletion (TCD). Following collection,
CD31T cells are enumerated by flow cytometry and a portion of the
product containing a dose of 3.0  107 CD31 cells/kg is set aside.
The remainder of the product is depleted of T cells by a two-step
method where the cells are first labeled with the anti-CD3monoclo-
nal antibody OKT3 attached to ferromagnetic microspheres. The
product is then incubated for 30min, washed twice, and passed
through a magnetized bead matrix that isolates the CD31 T cells
(CliniMACS; Miltenyi Biotec, Duarte CA). The T cell depleted
product is then combined with the set aside portion of the product
containing 3.0  107 CD31 cells/kg for the transplant. Three sepa-
rate procedures revealed 3.2 6 0.7 log TCD for the depleted prod-
uct. Recovery of other cellular components in the TCD product was
as follows: B cells 75.4% 6 17.5, NK cells 33.9% 6 30.3, CD346
cells 42.0% 6 8.0. Viability of the TCD product was 97.1% 6 1.9
and sterility assessment revealed all cultures to be free of organisms
following 14 days culture. Taken together, these data confirm
that partial TCD can be accomplished in a closed system allowing
standardization of graft T cell content.120
THE IMPORTANCE OF GRAFT CELL COMPOSITION TO OUTCOME AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Svenberg, P.1,3, Ringden, O.1, 2, Uzunel, M.1 1,2,3Karolinska University
Hospital, Huddinge, Sweden
Background: Stem cell dose has been shown to be important for
outcome in patients who undergo stem cell transplantation (SCT).
Grafts may contain varying amounts of different cell populations like
CD31, CD191, CD561, CD41 and CD81 immunocompetent
cells, whose role for clinical outcome is less clear.
Patients and Methods: We analyzed 591 patients who under-
went SCT at Karolinska University Hospital, Huddinge between
1998 to 2007 and correlated FACS results of the above mentioned
cell populations to clinical outcome. Most patients (76%) had he-
matological malignancies. 58% of the patients received a myeloa-
blative conditioning regimen, 62% were given peripheral blood
stem cells (PBSC) and in 58% of the transplants an unrelated donor
was used.
Results: As expected, PBSC contained much higher levels of all
different cell populations as compared to BM. We found that pa-
tients reciving high numbers of CD41, and CD81 cells had signif-
icantly more rapid engraftment. Also, a CD41 level above 200 
10(6)/kg was correlated to higher risk of developing acute GVHD
grades II-IV (41%) as compared to patients receiving below this level
(24%) (p\0,037).While the incidence of bacteria sepsis was lower in
patients receiving a high number of cell dose (CD3, CD19, CD56),
no correlation between cell dose and CMV reactivation was found.
Relapse free- and overall survivals were not significantly affected
by the different cell populations.
Conclusion: Grafts containing high numbers of CD41 cells is
a risk factor for developing severe acute GVHD but survival rates
were not significantly correlated to graft composition.HEMATOPOIESIS/MESENCHYMAL CELLS
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HLA MISMATCHED MSC SUPPRESS T LYMPHOCYTE ALLORESPONSES IN
VITRO AND DO NOT INDUCE IMMUNOLOGICAL MEMORY IN RECIPIENTS
OF MSC INFUSION
Sundin, M.1, Barrett, J.2, Ringden, O.1, Uzunel, M.1, Lonnies, H.1,
Dackland, A.-L.3, Christensson, B.3, Le Blanc, K.4 1Karolinska Institutet,
Stockholm, Sweden; 2National Institute of Health, Bethesda, MD; 3Kar-
olinska Institutet, Stockholm, Sweden; 4Karolinska Institutet and Karolin-
ska University Hospital Huddinge, Stockholm, Sweden
Multipotent mesenchymal stromal cells (MSC) are increasingly
used to treat refractory graft-versus-host-disease and other com-
plications in HLA-matched and mismatched hematopoietic stem
cell transplantation (HSCT) patients. We evaluated immunoge-nicity of human allogeneic MSC infused post-transplant to
HLA-mismatched, i.e. patients undergoing HSCT.We compared
recipient lymphocyte response to MSC and peripheral blood lym-
phocytes (PBL) from theMSC or third party donors before and af-
ter infusion, and lymphocyte responses to MSC and to PBL from
the MSC donor in primary and secondary challenge using 3H-ty-
midine. MSC recipients displayed in median responses less than
500 counts per minute (CPM) to infused third party MSC 1
week to 6 months following infusion. However, the recipients re-
sponded normally to MSC donor lymphocytes, .1000 CPM
(p\0.005), and third party lymphocytes, .5000 CPM
(p\0.005). MSC failed to prime responder lymphocytes to rechal-
lenge with PBL, as the responses was \10 000 versus .30 000
CPM for the corresponding control (p\0.05). On MSC rechal-
lenge of lymphocytes primed with PBL from the MSC donor,
only responses\500 CPM occurred. MSC upregulated lympho-
cyte gene expression of CD25, IFN-g, FoxP3, CTLA-4 and IL-
10 upon MSC/PBL co-culture and MSC presence in mixed
lymphocyte cultures. Unprimed and primed responder lympho-
cytes expanded and proliferated poorly to MSC as stimuli, evalu-
ated by flow cytometry. The MSC failed to induce CD251
(activated) or CD571 (effector) CD41 or CD81 subsets and
only inconsistently induced FoxP31 regulatory T lymphocytes.
These results confirm in vivo and in vitro that infused MSC are
weakly immunogenic and do not induce significant immunological
memory in HLA-disparate recipients.122
DOUBLE CORD BLOOD TRANSPLANTATION (CBT) WITH EX-VIVO EX-
PANSION (EXP) OF ONE UNIT UTILIZING A MESENCHYMAL STROMAL
CELL (MSC) PLATFORM
de Lima, M.1, McNiece, I.2, McMannis, J.1, Hosing, C.1, Kebraei, P.1,
Komanduri, K.1, Worth, L.1, Staba, S.1, Cooper, L.1, Petropolous, D.1,
Lee, D.1, Jones, R.1, Nieto, Y.1, Andersson, B.1, Korbling, M.1,
Alousi, A.1, Qazilbash, M.1, Popat, U.1, Khouri, I.1, Bollard, C.3,
Leen, A.3, Rondon, G.1, Molldrem, J.1, Champlin, R.1, Simmons, P.4,
Shpall, E.1 1University of Texas M.D. Anderson Cancer Center;
2University of Miami; 3Baylor College of Medicine; 4University of Texas
Institute of Molecular Medicine
Delayed or failed engraftment is a frequent complication of CBT.
We developed an approach that involves ex vivo co-culture of CB
mononuclear cells with third party marrow derived MSCs. Patients
must have 2 CB units matched in at least 4/6 HLA antigens, with
a minimum of 1 107 TNC/Kg per unit. A family member matched
in at least 2/6 antigens or more serves as the marrow-derived MSC
donor.
Methods: Diagnoses: AML/MDS (N 5 4), ALL (N 5 1), and
CLL (N5 1).One patientwas inCR and 5 had active disease (1 failed
a previous CBT). Preparative regimen: myeloablative melphalan
(140mg/m2), thiotepa (10mg/kg), fludarabine (160mg/m2), and rab-
bit ATG (3 mg/kg). GVHD prophylaxis: tacrolimus and MMF.
Median weight was 57 Kg (range, 14–79). Donor-recipient HLA
matching was 5 of 6 in 35% of the cases and 4 of 6 in 65%. Ex-
vivo EXP: 100 ml of marrow was aspirated from the family donor
and MSCs were generated in 10 T175 flasks. The CB unit with
the lowest TNC dose was thawed, and placed into flasks containing
confluent layers of MSCs in EXP media with SCF, FLT3, G-CSF
and TPO. After 7 days at 37C, the non-adherent cells were re-
moved, and placed into one-liter Teflon-coated culture bags and cul-
tured for an additional 7 days (14 days total); 50 ml of media/growth
factors was added to the flasks to culture the remaining adherent
layer during that time period. On day 14 the cells were washed and
infused along with a 2nd unmanipulated unit.
Results: There were no toxicities attributable to EXP. The me-
dian fold EXP was 12 (1–13) for TNC and 12 (0–27) for CD341
cells. Median time to neutrophil and platelet engraftment was
14.5 days (12–23) and 31 days (25–51). All patients (n 5 6)
engrafted neutrophils and platelets and became complete donor(s)
chimeras. Chimerism: 1 unit dominated in all patients; 2 patients
have mixed donors chimerism 4 months after CBT, with 5%
and 20% of the EXP unit contributing to hemopoiesis. Three pa-
tients had no evidence of EXP unit-derived hemopoiesis after day
130, while 1 patient is 100% donor but the contributing unit
48 Poster Session-Ihas not been identified at the time of this report. Five patients are
alive (3–13 mo) while 1 patient died 12 mo. after CBT due to pneu-
monia.
Conclusion: Preliminary analysis suggests that ex vivo EXP in
MSC-CB is feasible and may provide rapid engraftment. Accrual
to the trial continues.123
CD41FOXP31 REGULATORY T CELLS MEDIATE SUPPRESSION OF COL-
ONY FORMING ACTIVITY OF LEUKEMIC AS WELL AS PRIMARY MYELOID
PROGENITORS
Urbieta, M., Levy, R.B. University of Miami Miller School of Medicine,
Miami, FL
CD41CD251Foxp31 regulatory T cells (Treg) are essential
intermediaries of peripheral self tolerance. The role of Treg as mod-
ulators of the adaptive and innate immune responses has been exten-
sively studied within the last decade. Our laboratory has previously
found that in addition to their ability to regulate such responses,
Treg cells also possess the capacity to inhibit the colony forming ac-
tivity of early hematopoietic progenitor cells (PC) of myeloid origin.
In vitro experiments demonstrated that co-cultures of bone marrow
PC with activated Tregs resulted in 60% decrease of CFU-IL3
levels. Suppression of CFU activity was contact dependent and in-
volved TGF-b1, a Treg cytokine with strong inhibitory properties
of early hematopoietic progenitors. To address the regulation by
Tregs on bone marrow PC in vivo, highly purified (.99.5%) Tregs
from B6-Foxp3gfp1 mice were co-infused with syngeneic bone
marrow into lethally irradiated, B6-wt recipients. Colony forming
activity of IL-3 sensitive myeloid progenitors was assessed one
week post-BMT and was significantly suppressed (p\0.02) in recip-
ients receiving co-infused Treg cells. Based on the ability to suppress
differentiation of primary hematopoietic PC populations, we hy-
pothesized that Tregs may also inhibit myeloid leukemia progenitor
populations. To test this hypothesis, the myeloid leukemia cell line
NFS-60 was examined. The expression of IL-3Ra on these leukemia
cells was confirmed by flow cytometry, consistent with their IL-3 de-
pendence for growth and survival. We co-cultured anti-CD3/CD28
activated Treg cells with NFS-60 cells for 2 days and examined their
CFU activity in rmIL3 supplemented methylcellulose cultures. Acti-
vated Tregs suppressed CFU levels  70%. This inhibition was
abolished in transwell cultures indicating the Treg effector activity
was contact dependent as observed for primary marrow progenitor
cell suppression. Addition of rTGF-b1 inhibited NSF-60 prolifera-
tion and experiments involving neutralization of bioactive TGF-b1
in Treg/NFS-60 co-cultures with mAb 1D11 are presently under-
way. We intend to investigate myeloid progenitor cell activity and
tumor cell proliferation in leukemia bearing recipients receiving au-
tologous hematopoietic cell transplants (HCT) together with Treg
populations.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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HIGH RISK OF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTI-
BODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTA-
TION
Ciurea, S.O., de Lima, M., Cano, P., Korbling, M., McMannis, J.,
Giralt, S., Shpall, E.J., Champlin, R.E., Fernandez-Vina, M. The
University of Texas M.D. Anderson Cancer Center, Houston, TX
Background: Haploidentical stem cell transplantation
(HaploSCT) is associated with a graft failure (GF) rate of up to
20%, the causes of which are currently unknown. We hypothesized
that anti-HLA antibodies (HLA AB) directed against donor specific
antigens are contributing to the development of GF in such patients.
Methods: 22consecutivepatients,who receiveda total of 25haploi-
dentical transplants, were evaluated prospectively for the presence of
HLAAB.The conditioning regimen consisted offludarabine,melpha-
lan and thiotepa previously described. The presence of antibodies wasdetermined by testing the patients’ sera with a panel of fluorescent
beads coated with single HLA antigens using a Luminexe platform;
results were interpreted as fluorescence intensity (FI) with FI\500
negative, and 500–1500, 1500–3000 and.3000 considered weak, in-
termediate and strong, respectively. HLA A, B, C, DRB1, DRB3/4/
5, DQB1 and DPB1 were typed by high resolution methods.
Results: 6/22 patients experienced GF. Five patients, all females
with median age 39 years, had intermediate or strong FI antibody
titers, directed against both HLA class I and II antigens, most com-
monly anti-HLA DRB1. Overall, 4/6 (67%) HaploSCT performed
in the in the presence of HLA AB developed GF as compared with
1/19 (5%) patientswhodid not have antibodies (P5 0.001).Moreover,
all 4 patients (100%) receiving aHaploSCT in the presence ofmoder-
ate to high DSA titers failed to engraft (Table). Patients with GF un-
derwent second transplants from the same donors. After the first
patient was identified to have GF in the presence of HLA antibodies,
treatmentwith rituximab andplasma exchangewas initiated; this treat-
ment appeared todecrease the antibody titers in 2/4patients enough to
allow engraftment (Table). No significant differences were found in
the #CD341 cells infused, # allelemismatched, and # of bonemarrow
blasts at the time of transplant between the two groups. A review of the
pregnancy history (all patients with HLA antibodies were females)
showed that themedian number of pregnancies was 3 in theGF group
(N5 5) as compared with 0 in the control group (N5 6) (P5 0.1). In
addition, the transfusion history identified a median of 37 units (range
17–65) transfused in the GF group (N 5 5) as compared with 15 the
control group (range 4–38) (N5 16) (P5 0.007).
Conclusion: A high rate of graft rejection was observed among
patients with donor-derived anti-HLA antibodies receiving
a HaploSCT.
Relationship between HLA antibody titers and engraftment in
5 patients who received a total of 8 haploidentical transplants
at MDACC
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111Y N/A N/AAB – antibody, R – rituximab, PE – plasma exchange, NT – not tested.125
FLUDARABINE, MELPHALAN AND THIOTEPA CONDITIONING FOR UNRE-
LATED DONOR CORD BLOOD TRANSPLANTATION
Ciurea, S.O., Kebriaei, P., Khouri, I., Qazilbash, M., Jones, R.,
Petropoulos, D., Worth, L.L., Alousi, A., Hosing, C., Cano, P.,
McMannis, J., Giralt, S., Fernandez-Vina, M., Shpall, E.J., de
Lima,M. University of TexasMDAnderson Cancer Center, Houston, TX
Cord blood transplantation (CBT) is an established therapy for
patients (pts) who lack a matched sibling or unrelated donor. How-
ever, the optimal type and intensity of the preparative regimen for
such pts is unclear. We studied a conditioning regimen consisting
of fludarabine, melphalan and thiotepa in adult pts receiving a CBT.
Methods: 37 pts, median age 31 years (2–57), median weight
73kg, with advanced hematologic malignancies (24 with acute leuke-
mia, 13 with lymphoma/CLL) were treated between 8/2003-5/2008.
